Book Cover
Home  |   Healthcare   |  Pharmaceutical Analytical Testing Outsourcing Market

Pharmaceutical Analytical Testing Outsourcing Market Size, Share, Growth, and Industry Analysis, By Type (Bioanalytical Testing, Method Development and Validation, Stability Testing), By Application (Small & Medium Enterprise, Large Enterprise), Regional Insights and Forecast to 2035

Trust Icon
1000+
GLOBAL LEADERS TRUST US

Pharmaceutical Analytical Testing Outsourcing Market Overview

The Global Pharmaceutical Analytical Testing Outsourcing Market size is projected at USD 14176.12 Million in 2026 and is expected to reach USD 27660.15 Million in 2035, growing at a CAGR of 7.71% from 2026 to 2035.

The Pharmaceutical Analytical Testing Outsourcing Market is expanding as pharmaceutical manufacturers increasingly rely on specialized laboratories for drug development, regulatory compliance, and quality assurance. Bioanalytical Testing represents approximately 38% of global outsourced analytical testing demand, supported by increasing requirements for drug concentration measurement, biomarker evaluation, and biological product characterization. Pharmaceutical companies are outsourcing complex analytical activities to access advanced instrumentation, specialized scientific expertise, and validated laboratory infrastructure. Growing development of biologics, personalized medicines, and complex therapeutic formulations is strengthening demand for reliable testing services. External laboratories provide analytical flexibility while helping pharmaceutical manufacturers manage changing development schedules. Increasing emphasis on data integrity, regulatory documentation, and efficient laboratory operations continues to support sustained industry development.

The USA Pharmaceutical Analytical Testing Outsourcing Market benefits from extensive pharmaceutical research activity, established biotechnology companies, and sophisticated regulatory oversight. North America accounts for approximately 53% of global market demand in rounded industry estimates, with the United States representing the principal regional contributor. American pharmaceutical manufacturers increasingly outsource bioanalytical assessments, method validation, and stability studies to specialized contract laboratories. Advanced analytical technologies, including chromatography and mass spectrometry, support complex drug development programs requiring precise measurements. Growing investment in biologics and specialized therapeutic products creates additional testing requirements. Pharmaceutical companies also prioritize laboratory partners offering dependable turnaround times, validated procedures, and comprehensive documentation. Expanding laboratory automation and integrated testing services support continued market development across the United States.

Global Pharmaceutical Analytical Testing Outsourcing Market Size, 2035 (USD Million)

Get Comprehensive Insights into the Market’s Size and Growth Trends

downloadDownload FREE Sample

Key Findings

  • Market Driver: Increasing pharmaceutical development complexity and regulatory testing requirements are accelerating laboratory outsourcing, with industry forecasts indicating approximately 8% annual growth as manufacturers seek specialized analytical capabilities and efficient development support.
  • Major Market Restraint: High laboratory investment requirements and demanding quality validation procedures restrict operational flexibility, with Method Development and Validation representing approximately 34% of outsourced analytical service demand.
  • Emerging Trends: Advanced bioanalytical technologies and automated laboratory workflows are strengthening outsourced testing capabilities, with Bioanalytical Testing accounting for approximately 38% of service demand across pharmaceutical development programs.
  • Regional Leadership: North America maintains market leadership with approximately 53% of global demand, supported by established pharmaceutical research infrastructure, extensive clinical development activity, and advanced regulatory testing requirements.
  • Competitive Landscape: Eurofins Scientific strengthens its competitive position through laboratory acquisitions and integrated pharmaceutical testing capabilities, maintaining approximately 8% market share according to rounded industry estimates.
  • Market Segmentation: Bioanalytical Testing leads product demand with approximately 38% share, while Large Enterprise dominates applications with approximately 68% share, reflecting extensive pharmaceutical development pipelines and recurring analytical requirements.
  • Recent Development: SGS SA expanded its North American bioanalytical capabilities through the acquisition of CMIC, adding a specialized laboratory facility covering 27,000 square feet to its pharmaceutical testing network.

The Pharmaceutical Analytical Testing Outsourcing Market is increasingly influenced by integrated testing services, advanced bioanalytical technologies, and automated sample processing. Bioanalytical Testing accounts for approximately 38% of outsourced analytical demand, reflecting growing requirements for evaluating complex pharmaceutical products and therapeutic candidates. Contract laboratories are adopting advanced mass spectrometry, chromatography, and specialized assay technologies to improve sensitivity and analytical reliability. Pharmaceutical developers increasingly prefer service providers capable of coordinating multiple analytical activities within consistent quality systems. Digital laboratory management also supports sample traceability, efficient documentation, and improved communication between manufacturers and external testing partners. These developments are encouraging analytical laboratories to strengthen scientific expertise while expanding their technical service portfolios.

Another important trend involves increasing investment in stability testing infrastructure and digitally connected laboratory operations. Stability Testing represents approximately 28% of global demand after rounding the published segment estimates, highlighting its importance throughout pharmaceutical development and commercialization. Manufacturers require reliable information about product degradation, storage conditions, and shelf-life characteristics. Contract laboratories are expanding controlled storage capabilities and integrating automated environmental monitoring with analytical testing schedules. Specialized stability programs are becoming increasingly important for sensitive biologics and complex pharmaceutical formulations. Digital data management helps laboratories maintain consistent records across extended testing periods. Pharmaceutical companies increasingly seek service providers offering coordinated analytical support, dependable regulatory documentation, and flexible capacity for changing product development requirements.

Market Dynamics

Driver

"Increasing pharmaceutical research complexity accelerates demand for specialized external analytical laboratories."

Growing pharmaceutical development complexity remains a major driver of analytical testing outsourcing. Industry forecasts indicate approximately 8% annual market growth, supported by increasing requirements for specialized scientific expertise and laboratory capacity. Pharmaceutical manufacturers must conduct detailed analytical evaluations throughout drug discovery, clinical development, and commercial manufacturing. Complex biologics and specialized therapeutic products often require sophisticated testing methods that are expensive to maintain internally. External laboratories provide access to advanced instrumentation and experienced scientific personnel without requiring pharmaceutical companies to establish every analytical capability independently. Outsourcing arrangements also help manufacturers manage changing testing requirements across development programs. Increasing regulatory scrutiny strengthens demand for validated methods, dependable documentation, and consistent analytical results.

Growing requirements for biological product characterization further strengthen market demand. Bioanalytical Testing accounts for approximately 38% of outsourced analytical services, demonstrating the importance of measuring drug concentrations, metabolites, and relevant biomarkers. Pharmaceutical companies increasingly develop complex therapeutic products requiring specialized assay procedures and sensitive analytical instruments. Contract laboratories support these requirements through method optimization, sample analysis, and regulated testing workflows. Outsourcing allows manufacturers to concentrate internal resources on core research and product development activities. Laboratories offering coordinated analytical services and reliable project management can strengthen long-term relationships with pharmaceutical customers. Continued investment in biological medicines is expected to sustain demand for technically advanced external testing capabilities.

Restraint

"High compliance requirements and specialized laboratory investments restrict outsourcing efficiency."

Expensive laboratory infrastructure and demanding regulatory obligations create significant restraints for pharmaceutical analytical testing providers. Method Development and Validation represents approximately 34% of market demand, reflecting extensive requirements for analytical precision, specificity, accuracy, and reproducibility. Laboratories must invest in advanced instrumentation, qualified personnel, validated software, and controlled operating environments. Compliance procedures require extensive documentation and periodic quality assessments. Smaller testing providers may encounter difficulties financing sophisticated equipment while maintaining competitive service pricing. Pharmaceutical customers also expect dependable turnaround times and consistent analytical performance. These combined requirements can restrict laboratory expansion and increase the operational complexity of outsourced testing programs.

Data integrity expectations and lengthy qualification procedures further influence laboratory outsourcing decisions. Large Enterprise customers represent approximately 68% of demand, and their extensive development programs often require detailed supplier evaluations before analytical work can begin. Pharmaceutical manufacturers must establish reliable communication procedures, quality agreements, and sample handling protocols with external partners. Analytical method transfers may require additional verification when laboratories use different equipment or operating procedures. Delays in qualification can affect development schedules and increase administrative workloads. Service providers must balance rigorous compliance requirements with customer expectations for flexibility and efficiency. Maintaining qualified personnel and consistently validated systems remains essential for successful long-term outsourcing relationships.

Opportunity

"Emerging pharmaceutical markets and advanced analytical technologies create substantial expansion opportunities."

Expanding pharmaceutical research and manufacturing activities across developing economies create opportunities for analytical testing service providers. Asia-Pacific represents approximately 12% of worldwide market demand in rounded regional estimates, with additional growth supported by pharmaceutical investment in India, China, and other regional economies. Manufacturers increasingly require laboratories capable of conducting analytical testing according to internationally recognized standards. Establishing specialized facilities near pharmaceutical manufacturing centers can improve sample transportation efficiency and customer accessibility. Regional partnerships also allow international providers to extend laboratory networks without duplicating every technical capability. Demand for scientifically qualified personnel, modern instrumentation, and reliable regulatory documentation is creating opportunities for laboratory infrastructure investment.

Advanced biological therapies and specialized analytical workflows provide further development opportunities. Large Enterprise customers account for approximately 68% of application demand, creating substantial requirements for coordinated analytical support across multiple drug development programs. Pharmaceutical manufacturers increasingly seek laboratories offering high-sensitivity analysis, specialized biological assays, and flexible sample processing capabilities. Digital laboratory systems can improve project visibility and reduce repetitive administrative activities. Investment in automated instrumentation and standardized method validation may strengthen operational productivity. Providers capable of integrating Bioanalytical Testing, Method Development and Validation, and Stability Testing can differentiate their services through comprehensive scientific support. Long-term partnerships may also improve testing continuity throughout product development and commercialization.

Challenge

"Maintaining analytical accuracy and consistent testing capacity remains a major operational challenge."

Maintaining consistent analytical performance across increasingly complex pharmaceutical products presents a significant industry challenge. Bioanalytical Testing represents approximately 38% of outsourced demand, requiring laboratories to process diverse sample types and deliver dependable quantitative results. Biological matrices can introduce analytical interference, while specialized therapeutic products may require customized assay development. Laboratories must carefully control sample preparation, instrument calibration, reference materials, and analytical documentation. Differences between laboratory procedures can complicate method transfer and comparability assessments. Skilled scientific personnel remain essential for identifying analytical variability and resolving technical problems. Maintaining quality while increasing sample throughput requires continuous investment in laboratory training, instrumentation, and validated operating systems.

Capacity management presents additional challenges because pharmaceutical testing demand varies according to clinical development milestones and manufacturing schedules. Stability Testing represents approximately 28% of rounded market demand, requiring extended sample management and reliable environmental control. Laboratories must reserve sufficient storage space and instrument availability without creating excessive unused capacity. Unexpected testing requests can compete with established schedules and increase operational pressure. Digital monitoring and efficient resource planning help providers manage these requirements. However, laboratories must preserve data integrity and regulatory compliance even when testing volumes fluctuate significantly. Providers capable of maintaining flexible capacity and dependable turnaround performance can strengthen customer confidence.

Segmentation Analysis

Global Pharmaceutical Analytical Testing Outsourcing Market Size, 2035

Get Comprehensive Insights on the Market Segmentation in this Report

download Download FREE Sample

By Types

Bioanalytical Testing: Bioanalytical Testing represents the leading service category because pharmaceutical developers require detailed analysis of drugs, metabolites, biomarkers, and biological therapeutic products. It accounts for approximately 38% of outsourced analytical testing demand in rounded market estimates. Laboratories utilize sophisticated chromatography, mass spectrometry, and biological assay technologies to measure substances within complex samples. These services support drug development decisions, pharmacokinetic assessments, and selected clinical research activities. Increasing investment in biologics and specialized therapeutic products strengthens demand for laboratories offering sensitive analytical methods, validated procedures, and reliable scientific interpretation.

Bioanalytical Testing is becoming increasingly specialized as pharmaceutical companies develop complex molecular therapies and personalized treatment approaches. Providers frequently evaluate 3 important analytical characteristics: sensitivity, selectivity, and reproducibility. Advanced instrumentation allows laboratories to measure low drug concentrations while addressing interference from biological samples. Automated sample preparation and digital analytical systems improve workflow consistency. Contract laboratories increasingly provide integrated support across nonclinical and clinical development programs. Manufacturers value service providers capable of maintaining scientific continuity and dependable documentation throughout extended pharmaceutical development activities.

Method Development and Validation: Method Development and Validation is essential for establishing reliable procedures used throughout pharmaceutical development and manufacturing. The category accounts for approximately 34% of outsourced analytical testing demand in rounded market estimates. Laboratories develop methods that accurately identify, separate, and quantify relevant pharmaceutical substances. Validation activities assess whether analytical procedures are suitable for their intended applications. Pharmaceutical manufacturers rely on these services to support consistent product quality and regulatory documentation. Increasing complexity of drug formulations encourages demand for specialized method optimization and scientifically qualified analytical providers.

Method Development and Validation services are increasingly supported by advanced instrumentation and digitally documented workflows. Laboratories commonly examine 3 fundamental performance characteristics: accuracy, precision, and specificity. Additional evaluations address analytical sensitivity, robustness, and operating range according to method requirements. Pharmaceutical companies frequently transfer analytical procedures between development laboratories and commercial manufacturing facilities. Contract providers must establish appropriate verification and documentation practices to preserve reliable results. Growing regulatory expectations and increasingly sophisticated pharmaceutical products continue to support demand for comprehensive method development capabilities.

Stability Testing: Stability Testing provides pharmaceutical manufacturers with information about product quality under defined storage and environmental conditions. It represents approximately 28% of outsourced analytical testing demand after rounding published segment estimates. Contract laboratories conduct controlled studies to evaluate physical, chemical, and biological changes throughout specified storage periods. Results help manufacturers establish suitable storage conditions and support shelf-life assessments. Advanced stability facilities are particularly important for temperature-sensitive products and complex formulations. Increasing demand for specialized testing infrastructure encourages pharmaceutical companies to work with external laboratories offering validated storage and analytical capabilities.

Stability Testing providers are investing in automated monitoring and expanded environmental storage infrastructure. Programs may evaluate 3 important conditions: temperature exposure, relative humidity, and storage duration. Pharmaceutical products require testing schedules that reflect their intended formulation and regulatory development requirements. Laboratories must maintain reliable environmental records and coordinate scheduled sample analysis. Digital laboratory systems can improve tracking and reduce administrative errors. Increasing complexity of biologics and combination products creates opportunities for specialized stability programs. Service providers offering flexible storage conditions and dependable analytical support can strengthen their relationships with pharmaceutical manufacturers.

By Applications

Small & Medium Enterprise: Small & Medium Enterprise pharmaceutical companies frequently outsource analytical testing because specialized laboratory infrastructure requires significant investment and scientific expertise. This application represents approximately 32% of global demand in rounded market estimates. Emerging pharmaceutical developers often manage limited internal laboratory capacity while conducting complex research and clinical development programs. External service providers offer access to validated analytical methods, advanced instruments, and qualified personnel. Outsourcing enables smaller companies to allocate resources toward product development while obtaining necessary testing support. Flexible service arrangements are particularly valuable when testing requirements change between development stages.

Small & Medium Enterprise customers increasingly seek integrated laboratory partnerships capable of supporting multiple analytical requirements. Outsourcing arrangements commonly cover 3 core activities: Bioanalytical Testing, Method Development and Validation, and Stability Testing. Consolidating these services can simplify project coordination and reduce administrative complexity. Smaller pharmaceutical developers value transparent communication, predictable delivery schedules, and scientific consultation. Contract laboratories offering adaptable project structures may strengthen participation among emerging biotechnology businesses. Continued growth in specialized therapeutic research supports opportunities for providers serving smaller development organizations.

Large Enterprise: Large Enterprise pharmaceutical companies dominate analytical testing outsourcing because they manage extensive development pipelines and recurring quality requirements. The segment accounts for approximately 68% of global demand in rounded market estimates. Multinational manufacturers utilize specialized external laboratories to supplement internal analytical capacity and access advanced scientific expertise. Complex drug development programs often require coordinated testing across several research and manufacturing facilities. External partnerships provide operational flexibility while supporting stringent documentation requirements. Large pharmaceutical organizations particularly value providers capable of maintaining consistent quality across geographically distributed testing programs.

Large Enterprise customers increasingly establish long-term laboratory relationships to improve development continuity and analytical capacity planning. Pharmaceutical programs commonly require coordination across 3 major stages: early development, clinical evaluation, and commercial manufacturing support. Service providers must maintain reliable communication and consistent analytical procedures throughout these activities. Advanced digital reporting systems help customers monitor testing progress and manage scientific information. Integrated outsourcing arrangements can reduce unnecessary laboratory transfers and improve resource utilization. Providers offering extensive testing networks and specialized expertise are positioned to address increasingly complex enterprise requirements.

Regional Outlook

Global Pharmaceutical Analytical Testing Outsourcing Market Share, by Type 2035

Get Comprehensive Insights into the Market’s Size and Growth Trends

download Download FREE Sample

North America

North America leads the Pharmaceutical Analytical Testing Outsourcing Market because of its extensive pharmaceutical research infrastructure and sophisticated laboratory capabilities. The region represents approximately 53% of global demand in rounded industry estimates. The United States contributes substantially through established biotechnology companies, pharmaceutical manufacturers, and specialized contract laboratories. Increasing development of biological medicines supports demand for sensitive analytical methods and dependable regulatory testing. Advanced laboratory automation and integrated outsourcing services continue strengthening the regional market.

Regional laboratories are expanding scientific capabilities to support increasingly complex pharmaceutical development programs. SGS acquired a 27,000-square-foot bioanalytical facility in Chicago, strengthening its North American analytical network. Pharmaceutical customers prioritize reliable sample analysis, validated methods, and transparent scientific documentation. Contract laboratories are investing in advanced equipment and digital workflow management. Continued pharmaceutical research activity supports demand for specialized analytical expertise.

Europe

Europe maintains a significant position through established pharmaceutical manufacturing, advanced scientific research, and extensive regulatory testing requirements. The region accounts for approximately 25% of global demand in rounded market estimates. Germany, France, Switzerland, and the United Kingdom support substantial laboratory outsourcing activity. Pharmaceutical manufacturers increasingly require specialized testing for biological products and complex formulations. Advanced analytical infrastructure and experienced scientific personnel strengthen the region's competitive position.

European laboratories continue investing in expanded stability storage and specialized analytical facilities. Intertek increased its pharmaceutical stability storage capacity to 625,000 litres at its Royston facility in the United Kingdom. This investment reflects growing requirements for controlled environmental storage and integrated laboratory services. Pharmaceutical manufacturers increasingly seek dependable testing partners capable of supporting complex product development. Regional demand also benefits from digital laboratory modernization and established quality management systems.

Asia-Pacific

Asia-Pacific is developing rapidly as pharmaceutical manufacturing, biotechnology research, and laboratory infrastructure continue expanding. The region accounts for approximately 12% of global outsourced analytical testing demand in rounded estimates. China, India, Japan, and South Korea contribute through pharmaceutical development and increasing adoption of external testing services. Regional laboratories are strengthening scientific capabilities to support international pharmaceutical customers. Cost competitiveness and growing technical expertise create opportunities for laboratory outsourcing providers.

Pharmaceutical testing requirements are increasing as regional manufacturers pursue international regulatory approvals. India is projected to achieve approximately 11% annual growth in pharmaceutical analytical testing outsourcing under rounded industry forecasts. Laboratories are investing in advanced analytical instruments and standardized operating procedures. International partnerships can improve access to specialized testing technologies. Continued development of pharmaceutical research infrastructure supports regional market expansion.

Middle East and Africa

Middle East and Africa represents an emerging market supported by healthcare investment and gradual development of pharmaceutical manufacturing infrastructure. The region accounts for approximately 4% of global demand in rounded industry estimates. Local pharmaceutical producers increasingly require analytical testing to support product quality and regulatory documentation. Specialized laboratories provide opportunities for method validation and stability studies. Growth remains influenced by scientific workforce availability and investment in qualified laboratory facilities.

Regional outsourcing opportunities are expanding alongside pharmaceutical manufacturing localization initiatives. Laboratories increasingly require capabilities covering 3 fundamental areas: sample characterization, analytical method verification, and product stability evaluation. International partnerships can improve technical training and quality management practices. Reliable laboratory infrastructure remains essential for supporting regulated pharmaceutical production. Investment in testing capabilities may strengthen long-term market participation.

Rest of World

Rest of World includes developing pharmaceutical markets outside the major regional groups. This category represents approximately 6% of global demand in the report's rounded geographic allocation. Pharmaceutical manufacturers increasingly recognize the importance of standardized testing and specialized laboratory expertise. Demand is influenced by local regulatory development, manufacturing capacity, and access to qualified analytical service providers. Smaller pharmaceutical organizations frequently rely on external laboratories to obtain advanced testing capabilities.

Market development depends on stronger laboratory infrastructure and consistent scientific training. Regional providers increasingly emphasize 3 essential service characteristics: reliable analytical results, regulatory documentation, and predictable testing schedules. International laboratory partnerships can improve access to specialized technologies. Expanding pharmaceutical manufacturing activity supports future outsourcing opportunities. Providers offering flexible services and dependable technical support may strengthen market participation.

List of Top Pharmaceutical Analytical Testing Outsourcing Companies

  • Exova Group
  • West Pharmaceutical Services
  • Intertek Group
  • Eurofins Scientific
  • Charles River Laboratories International
  • Toxikon
  • Boston Analytical
  • Pace Analytical Services
  • Pharmaceutical Product Development
  • SGS SA

Top 2 Companies with Highest Market Share

  • Eurofins Scientific: Eurofins Scientific holds an estimated 8% share of the global Pharmaceutical Analytical Testing Outsourcing Market in rounded published industry estimates, supported by its international laboratory network, specialized bioanalytical capabilities, and integrated pharmaceutical testing services.
  • Charles River Laboratories International: Charles River Laboratories International holds an estimated 7% share of the global Pharmaceutical Analytical Testing Outsourcing Market in rounded published industry estimates, supported by advanced bioanalytical services, drug development expertise, and extensive laboratory capabilities.

Investment Analysis and Opportunities

Investment in the Pharmaceutical Analytical Testing Outsourcing Market increasingly focuses on advanced laboratory instrumentation, automated workflows, and expanded bioanalytical capacity. Bioanalytical Testing represents approximately 38% of outsourced analytical service demand, making specialized scientific infrastructure an important investment priority. Contract laboratories are acquiring sophisticated analytical instruments and developing integrated services for complex pharmaceutical products. Automation can improve sample handling consistency and reduce repetitive laboratory activities. Pharmaceutical manufacturers increasingly prefer providers capable of coordinating multiple analytical requirements through established quality systems. Investment opportunities are particularly attractive in laboratories offering advanced biological assays, validated analytical procedures, and flexible development support. Expanding pharmaceutical pipelines create additional requirements for qualified scientific personnel and dependable testing infrastructure.

Regional laboratory acquisitions and capacity expansion are also strengthening investment opportunities. Eurofins Scientific announced an agreement to acquire a North American life sciences testing business operating 27 laboratories and facilities, demonstrating the importance of established laboratory networks. The transaction was announced rather than completed at the time of disclosure. Investors increasingly prioritize providers offering integrated analytical services and broad customer accessibility. Advanced stability storage, digital laboratory platforms, and specialized method development capabilities create opportunities for technical differentiation. Growing pharmaceutical research activity across emerging markets may encourage regional partnerships and new testing facilities. Companies combining scientific expertise with dependable quality management can strengthen long-term customer relationships.

New Product Development

New Product Development in pharmaceutical analytical testing increasingly emphasizes high-sensitivity assays, automated sample preparation, and digital laboratory management. Charles River Laboratories International highlighted bioanalysis as a strategic growth area, targeting approximately 8% annual growth in its outsourced bioanalysis opportunity assumptions. Laboratories are refining analytical methods for complex therapeutic products requiring reliable quantitative measurements. Advanced mass spectrometry and automated biological assays can improve consistency across demanding testing programs. Digital laboratory platforms support sample tracking, controlled documentation, and more efficient scientific communication. Service providers are also developing integrated workflows that connect analytical method validation with subsequent clinical sample analysis. These developments help pharmaceutical manufacturers manage complex testing requirements while maintaining rigorous scientific standards.

Stability testing infrastructure and improved laboratory quality systems represent another important innovation direction. Intertek expanded its controlled pharmaceutical stability storage capacity to 625,000 litres, strengthening support for complex pharmaceutical development programs. Modern stability facilities provide specialized temperature and humidity conditions suitable for different formulations. Automated monitoring systems can improve environmental control and documentation throughout extended study periods. Laboratories are also introducing flexible sample scheduling and digitally connected analytical reporting. Pharmaceutical manufacturers increasingly require testing partners capable of coordinating stability programs with formulation evaluation and regulatory documentation. These improvements strengthen service reliability and support the development of sensitive pharmaceutical products.

Five Recent Developments

  • April 2026 – Pace Analytical Services: Pace Life Sciences expanded its microbial limits testing laboratory at its Lebanon, New Jersey facility, increasing analytical capacity and improving laboratory workflow efficiency. The expansion supports higher sample volumes and strengthens regulated testing services for pharmaceutical and biotechnology customers.
  • May 2026 – Intertek Group: Intertek expanded its GMP pharmaceutical stability storage facility in Royston, United Kingdom, increasing total controlled storage capacity to 625,000 litres. The development supports specialized pharmaceutical stability programs and provides additional environmental storage options for complex formulations and sensitive biological products.
  • June 2026 – SGS SA: SGS acquired CMIC, a specialized bioanalytical testing company based in Chicago, United States. The acquisition added a 27,000-square-foot GLP-compliant laboratory, strengthening capabilities for nonclinical and clinical bioanalysis across pharmaceutical development programs.
  • July 2026 – Eurofins Scientific: Eurofins announced an agreement to acquire Element Materials Technology's North American Life Sciences Testing Services business, comprising 27 laboratories and facilities and approximately 750 employees. The proposed acquisition strengthens its pharmaceutical testing network and expands geographic coverage across North America.
  • September 2026 – Charles River Laboratories International: Charles River announced its Pathway to Purpose strategy, emphasizing scientific portfolio development, laboratory automation, and expanded bioanalytical capabilities. The company identified more than 18,000 users of its Apollo digital platform, supporting enhanced scientific services and customer collaboration.

Report Coverage

The Pharmaceutical Analytical Testing Outsourcing Market report examines industry development, analytical technologies, competitive conditions, and pharmaceutical testing requirements across 3 service categories and 2 enterprise applications. Coverage includes Bioanalytical Testing, Method Development and Validation, and Stability Testing, with attention to laboratory processes, regulatory expectations, and scientific capabilities. Application analysis evaluates Small & Medium Enterprise and Large Enterprise customers, considering their different laboratory outsourcing requirements. The report also examines analytical instrumentation, automated laboratory operations, data integrity, and quality management practices. Technology development and laboratory capacity expansion are evaluated alongside challenges involving specialized staffing, analytical consistency, and changing pharmaceutical development needs.

Regional coverage considers 5 geographic markets, emphasizing differences in pharmaceutical research infrastructure, laboratory availability, and outsourced testing adoption. Competitive analysis includes 10 specified companies and examines their laboratory capabilities, strategic partnerships, acquisition activities, and technical service development. Investment coverage evaluates advanced bioanalytical platforms, integrated testing services, and expanding laboratory infrastructure. Product development analysis considers high-sensitivity analytical methods, digital data management, and specialized stability testing capabilities. The report provides a structured examination of operational and technological factors shaping external analytical testing demand across pharmaceutical research, development, and regulated manufacturing activities.

Pharmaceutical Analytical Testing Outsourcing Market Report Coverage

REPORT COVERAGE DETAILS

Market Size Value In

USD 14176.12 Million in 2026

Market Size Value By

USD 27660.15 Million by 2035

Growth Rate

CAGR of 7.71% from 2026-2035

Forecast Period

2026 - 2035

Base Year

2025

Historical Data Available

Yes

Regional Scope

Global

Segments Covered

By Type :

  • Bioanalytical Testing
  • Method Development and Validation
  • Stability Testing

By Application :

  • Small & Medium Enterprise
  • Large Enterprise

To Understand the Detailed Market Report Scope & Segmentation

download Download FREE Sample

Frequently Asked Questions

The global Pharmaceutical Analytical Testing Outsourcing Market is expected to reach USD 27660.15 Million by 2035.

The Pharmaceutical Analytical Testing Outsourcing Market is expected to exhibit a CAGR of 7.71% by 2035.

Exova Group, West Pharmaceutical Services, Intertek Group, Eurofins Scientific, Charles River Laboratories International, Toxikon, Boston Analytical, Pace Analytical Services, Pharmaceutical Product Development, SGS SA

In 2026, the Pharmaceutical Analytical Testing Outsourcing Market value will reach at USD 14176.12 Million.

faq right

Our Clients

Captcha refresh

Trusted & Certified